Want to join the conversation?
$BIIB 2Q15 PR: TECFIDERA revenues were $883MM, up 7% vs. $700MM in 2Q14; TECFIDERA now the most prescribed oral MS therapy globally. Interferon revenues, including AVONEX and PLEGRIDY, were $690MM vs. $774MM in 2Q14. TYSABRI revenues were $463MM vs. $533MM in 2Q14. Revenues for FAMPYRA and FUMADERM were $34MM vs. $38MM in 2Q14.
Looks like $BAC is regaining its lost reputation after the 2008 financial crisis. I hope the stock will flourish under Trump.
$BA won a $22 billion deal from SpiceJet, their largest order from an Indian airline.
$FB stock remained in the green territory after Raymond James upgraded shares to strong buy from outperform, on expectations that overall 4Q16 ad spending was strong.
$ARRY Good day for the stock, jumped 7%. Great gains !
2017 was supposed to be another record year for automotive industry. Still, $F Ford thinks its profit will dip in 2017..!!